London, ENGLAND – A British based pharmaceutical company, GW Pharma, is currently undergoing advanced clinical trials on its marijuana based mouth spray. The drug, Sativex, is already available in Canada, eight European countries and New Zealand, and recent trials should open up the drug to the United States, if it gains FDA approval.
Sativex is the first of its kind, as it uses raw marijuana extracts, tetra-hydra-cannibol and cannabidiol, rather than synthetic marijuana used in previously approved drugs. GW Pharma hopes that Sativex will be approved as early as 2013. Sativex has been developed particularly for multiple-sclerosis and cancer patients, and its spray format makes it easy and safe to introduce THC into the blood stream.
While doctors and patients have been skeptical of medical marijuana, and Sativex, as a treatment for multiple-sclerosis, there are a number of sponsored studies, in order to establish any benefits that marijuana may have to offer. It is essentially a waiting game at this point, as we continue to await further studies on the effects of marijuana and its overall potential in the medical field.
About Ann Flannigan
No related posts.
Subscribe to Herbisto
Search The Stash
Herbisto News Right to Your Inbox
Most Popular Posts
Find Us on Facebook